CN113855664A - Pharmaceutical composition for inhibiting proliferation and migration of triple negative breast cancer cells and application thereof - Google Patents
Pharmaceutical composition for inhibiting proliferation and migration of triple negative breast cancer cells and application thereof Download PDFInfo
- Publication number
- CN113855664A CN113855664A CN202111047163.1A CN202111047163A CN113855664A CN 113855664 A CN113855664 A CN 113855664A CN 202111047163 A CN202111047163 A CN 202111047163A CN 113855664 A CN113855664 A CN 113855664A
- Authority
- CN
- China
- Prior art keywords
- mol
- chrysosplenetin
- breast cancer
- negative breast
- sbfi
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Gynecology & Obstetrics (AREA)
- Emergency Medicine (AREA)
- Oncology (AREA)
- Pregnancy & Childbirth (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention discloses a pharmaceutical composition for inhibiting proliferation and migration of triple negative breast cancer cells, which is characterized by comprising the following components in part by weight: the pharmaceutical composition comprises chrysosplenetin B and a small molecule inhibitor SBFI-26; the concentration of the chrysosplenetin B is 0.25 multiplied by 10‑4‑1×10‑ 4mol/L, the concentration of the small molecule inhibitor SBFI-26 is 1x 10‑4mol/L; the chrysosplenetin and the small molecule inhibitor SBFI-26 are applied to preparing a pharmaceutical composition for inhibiting the proliferation and migration of triple-negative breast cancer cells; the pharmaceutical composition is used for triple negative milkAdenocarcinoma can effectively promote the death of MDA-MB-231 cells of triple-negative breast cancer and inhibit the migration of MDA-MB-231 cells of triple-negative breast cancer, and the pharmaceutical composition has low toxicity to normal cells.
Description
Technical Field
The invention relates to the technical field of medical biology, in particular to application of a pharmaceutical composition for inhibiting proliferation and migration of triple negative breast cancer cells.
Background
The breast cancer is the most common malignant tumor of women all over the world, accounts for about 25 percent of the malignant tumors of the women, is the top of various tumors of the women, and the incidence rate is in a rapid rising trend in recent years. Triple Negative Breast Cancer (TNBC), immunohistochemistry, shows that Estrogen Receptor (ER), Progesterone Receptor (PR), and HER-2 are all Negative. As a subtype of breast cancer, TNBC accounts for 15% to 20% of all breast cancers. TNBC is clinically characterized by more aggressive pathological features, including higher recurrence rate, drug resistance to chemotherapeutic drugs, more frequent distant metastasis (a process in which tumor cells are transferred from an originally occurring site to other sites of the body via an invasion circulatory system and continue to grow, also called malignant metastasis) when diagnosed, and poorer prognosis. Clinical treatment methods for TNBC include surgery, chemotherapy and radiation therapy, with chemotherapy being the primary therapy in medicine. Despite the diversity of chemotherapeutic regimens, 35% of TNBC patients develop recurrent metastases and have a short survival time.
Because the TNBC cell surface has no special cell surface receptor, the triple negative breast cancer has the characteristics of strong invasiveness, advanced recurrence time, high incidence rate of malignant metastasis, rapid disease progression, limited treatment means, poor curative effect, disease-free survival rate, lower overall survival rate, shortened overall survival time and the like. The existing medicine for treating triple negative breast cancer has the defects of high toxicity and low treatment remission rate.
Disclosure of Invention
The invention aims to overcome the defects of the prior art and provide the application of the pharmaceutical composition for inhibiting the proliferation and migration of the triple negative breast cancer cells so as to achieve the aims of reducing the survival rate of the triple negative breast cancer cells and inhibiting the migration of the cells.
The purpose of the invention is realized by the following technical scheme: a pharmaceutical composition for inhibiting proliferation and migration of triple negative breast cancer cells, the pharmaceutical composition comprising chrysosplenetin and a small molecule inhibitor SBFI-26; the concentration of the chrysosplenetin B is 0.25-1 × 10-4mol/L, the concentration of the small molecule inhibitor SBFI-26 is 1x 10-4mol/L。
Further, the concentration of the chrysosplenetin B is 0.25 multiplied by 10-4mol/L, the concentration of the small molecule inhibitor SBFI-26 is 1x 10-4mol/L。
The application of the chrysosplenetin and the small molecule inhibitor SBFI-26 in preparing the pharmaceutical composition for inhibiting the proliferation and migration of the triple-negative breast cancer cells.
The molecular formula of the chrysosplenetin B is C19H18O8The chemical structural formula is as follows:
for inhibiting triple negative breast cancer MDA-MB-231 cell proliferation and migration;
the molecular formula of the small molecule inhibitor SBFI-26 is C28H22O4The chemical structural formula is as follows:
for inhibiting triple negative breast cancer MDA-MB-231 cell proliferation and migration; the two drugs act synergistically under a certain dosage to promote the death of MDA-MB-231 cells of triple negative breast cancer and inhibit the migration of MDA-MB-231 cells of triple negative breast cancer.
The invention has the beneficial effects that: the pharmaceutical composition provided by the invention is applied to triple negative breast cancer, can effectively promote the death of triple negative breast cancer MDA-MB-231 cells and inhibit the migration of triple negative breast cancer MDA-MB-231 cells, and has low toxicity to normal cells.
Drawings
FIG. 1 is a graph of proliferation inhibition of chrysosplenetin for triple negative breast cancer MDA-MB-231 cells;
FIG. 2 is a graph showing the 24h cell survival of triple negative breast cancer cells when chrysosplenin is applied to the triple negative breast cancer cells;
FIG. 3 is a graph of 24h cell survival rate of Sciadopityl B combined with SBFI-26 on triple-negative breast cancer cells;
FIG. 4 is a graph of the inhibition of migration of triple negative breast cancer cells by using chrysosplenetin in combination with SBFI-26;
FIG. 5 is a graph showing the effect of yamamoto B in combination with SBFI-26 on the migration inhibition of triple-negative breast cancer cells.
Detailed Description
The technical solutions of the present invention are further described in detail below with reference to the accompanying drawings, but the scope of the present invention is not limited to the following.
Example 1
A pharmaceutical composition for inhibiting proliferation and migration of triple negative breast cancer cells, the pharmaceutical composition comprising chrysosplenetin and a small molecule inhibitor SBFI-26; the concentration of the chrysosplenetin B is 0.25 multiplied by 10-4mol/L, the concentration of the small molecule inhibitor SBFI-26 is 1x 10-4mol/L。
Example 2
A pharmaceutical composition for inhibiting proliferation and migration of triple negative breast cancer cells, the pharmaceutical composition comprising chrysosplenetin and a small molecule inhibitor SBFI-26; the concentration of the chrysosplenetin B is 0.5 multiplied by 10-4mol/L, the concentration of the small molecule inhibitor SBFI-26 is 1x 10-4mol/L。
Example 3
A pharmaceutical composition for inhibiting proliferation and migration of triple negative breast cancer cells, the pharmaceutical composition comprising chrysosplenetin and a small molecule inhibitor SBFI-26; the concentration of the chrysosplenetin B is 0.75 multiplied by 10-4mol/L, the concentration of the small molecule inhibitor SBFI-26 is 1x 10-4mol/L。
Example 4
A pharmaceutical composition for inhibiting proliferation and migration of triple negative breast cancer cells, the pharmaceutical composition comprising chrysosplenetin and a small molecule inhibitor SBFI-26; the concentration of the chrysosplenetin B is 1 multiplied by 10-4mol/L, the concentration of the small molecule inhibitor SBFI-26 is 1x 10-4mol/L。
Example 5
A pharmaceutical composition for inhibiting proliferation and migration of triple negative breast cancer cells, the pharmaceutical composition comprising chrysosplenetin; the concentration of the chrysosplenetin B is 0.25 multiplied by 10-4mol/L。
Example 6
A pharmaceutical composition for inhibiting proliferation and migration of triple negative breast cancer cells, the pharmaceutical composition comprising chrysosplenetin; the concentration of the chrysosplenetin B is 0.5 multiplied by 10-4mol/L。
Example 7
A pharmaceutical composition for inhibiting proliferation and migration of triple negative breast cancer cells, the pharmaceutical composition comprising chrysosplenetin; the concentration of the chrysosplenetin B is 0.75 multiplied by 10-4mol/L。
Example 8
A pharmaceutical composition for inhibiting proliferation and migration of triple negative breast cancer cells, the pharmaceutical composition comprising chrysosplenetin; the concentration of the chrysosplenetin B is 1 multiplied by 10-4mol/L。
Example 9
A pharmaceutical composition for inhibiting proliferation and migration of triple negative breast cancer cells, the pharmaceutical composition comprising a small molecule inhibitor SBFI-26; the concentration of the SBFI-26 is 1 multiplied by 10-4mol/L。
Blank control group
All blank controls were treated with a volume fraction of 0.1% DMSO.
Experiments were performed with the drug ratios referred to in examples 1-9 and a blank control group to examine the effect on proliferation, survival and migration of triple negative breast cancer MDA-MB-231 cells.
1. Preparation, preservation and management of chrysosplenetin and SBFI-26 mother liquor
(1) Weighing 0.0037g of chrysosplenetin B, dissolving the weighed chrysosplenetin B in 100 mu L of DMSO, uniformly mixing by vortexing to obtain 0.1mol/L chrysosplenetin B, and respectively filling 5 centrifugal tubes of 50 mu L with 1 multiplied by 10-420 mu L of chrysosplenetin at mol/L, and then placing the centrifuge tube in an ultra-low temperature refrigerator at minus 80 ℃ for storage.
(2) 10mg of SBFI-26 was weighed, dissolved in 1mL of DMSO, vortexed to obtain 10mg/mL of SBFI-26, 200. mu.L of 10mg/mL of SBFI-26 was placed in 5 1.5mL centrifuge tubes, and the centrifuge tubes were stored in an ultra-low temperature freezer at-80 ℃.
2. Regulation and control experiment of chrysosplenetin on MDA-MB-231 cells of triple-negative breast cancer
(1) Triple negative breast cancer MDA-MB-231 cell culture fluid in logarithmic growth phase is inoculated into 96-well plates at 5000/well in 5% CO2Overnight culture in a cell culture box at 37 ℃ to make the cells adhere to the wall;
(2) preparing DMSO with volume fraction of 0.1% at a concentration of 0.25 × 10-4mol/L、0.5×10-4mol/L、0.75×10-4mol/L and 1X 10-4B, chrysosplenetin in mol/L;
the specific operation is as follows:
(2.1) 4 1.5mL centrifuge tubes and one 5mL centrifuge tube were labeled "0.1% DMSO, 0.25X 10- 4mol/L chrysosplenetin B, 0.5X 10-4mol/L chrysosplenetin B, 0.75X 10-4mol/L of chrysosplenetin B and 1 × 10-4mol/L chrysosplenetin B ";
(2.2) thereafter, 5. mu.L of 100mM chrysosplenetin was applied to the label "1X 10-4Adding 4995 μ L RPMI Medium 1640 Basic (1X) into a centrifugal tube containing mol/L chrysosplenetin, and mixing to obtain a mixture of 1 × 10-4mol/L chrysosplenetin B;
(2.3) thereafter, 1X 10 of (2.2) were successively sampled-4250, 500 and 750 mu L of chrysosplenetin at mol/L of the mark' 0.25 multiplied by 10-4mol/L chrysosplenetin B, 0.5X 10-4mol/L chrysosplenetin B, 0.75X 10-4In a centrifugal tube of mol/L chrysosplenetin, sequentially adding 750 mu L, 500 mu L and 250 mu L of RPMI Medium 1640 Basic (1X), and respectively and uniformly mixing by vortex for later use; meanwhile, 1 microliter of DMSO is taken out and put in a centrifugal tube marked with 0.1 percent DMSO, 999 microliter of RPMI Medium 1640 Basic (1X) is added, and vortex mixing is carried out for standby;
(2.4) the cell culture medium in the 96-well plate was discarded, and 100. mu.L of the corresponding medium was added to each well, followed by 0.25X 10- 4mol/L chrysosplenetin B, 0.5X 10-4mol/L chrysosplenetin B, 0.75X 10-4mol/L of chrysosplenetin B and 1 × 10-4Treating cell culture solution with 0.1% DMSO containing Cinereidin in mol/L and 6 repeats per group; then continuously culturing in a cell culture box for 24h, and taking a picture under an inverted microscope for recording, wherein the magnification is 200 times;
(2.5) then, respectively removing the culture medium, adding 100 mu L of new culture medium into each well, adding 10 mu L of CCK8 reagent into each well, incubating for 2h at 37 ℃, and then measuring A450 by using a full-automatic enzyme standard instrument;
(2.6) calculating the cell survival rate according to a cell survival rate formula I; and the data were processed and plotted using GraphPad Prism software.
Cell survival rate (%) [ (As-Ab)/(Ac-Ab ] × 100% > (r)
As: experimental well (containing cell culture medium, CCK, toxic substance)
Ac: control wells (containing cell culture medium, CCK, no toxic substance)
Ab: blank well (Medium without cell and toxic substances, CCK)
The results of the experiment are shown in FIGS. 1 and 2, and it can be seen from FIG. 1 that 0.25X 10-4The MDA of triple negative breast cancer can be caused by the mol/L of chrysosplenin BThe morphological shrinkage of-MB-231 cells indicates that the chrysosplenetin can inhibit the proliferation of MDA-MB-231 cells with triple negative breast cancer, and as can be seen in FIG. 2, 0.25X 10-4mol/L、0.5×10-4mol/L、0.75×10-4mol/L and 1X 10-4The mol/L of chrysosplenetin can reduce the survival of triple negative breast cancer MDA-MB-231 cells, and shows that chrysosplenetin can inhibit the proliferation of triple negative breast cancer MDA-MB-231 cells.
3. Regulation of triple-negative breast cancer MDA-MB-231 cells by combination of chrysosplenetin and SBFI-26
(1) Triple negative breast cancer MDA-MB-231 cells in logarithmic growth phase were seeded at 5000/well in 96-well plates, 100. mu.L of the corresponding medium per well, in "5% CO2Allowing cells to adhere to the wall overnight in a cell culture box under the condition of 37 ℃;
(2) preparing DMSO with volume fraction of 0.1% at a concentration of 0.25 × 10-4mol/L、0.5×10-4mol/L、0.75×10-4mol/L and 1X 10-4The concentration of the chrysosplenetin B is 1 multiplied by 10-4mixed solution of mol/L SBFI-26;
the specific operation is as follows:
(2.1) 4 1.5mL centrifuge tubes and one 5mL centrifuge tube were labeled "0.1% DMSO, 0.25X 10- 4mol/L chrysosplenetin + SBFI-26, 0.5X 10-4mol/L chrysosplenetin + SBFI-26, 0.75 × 10-4mol/L chrysosplenetin + SBFI-26 and 1 × 10-4mol/L chrysosplenetin + SBFI-26 ";
(2.2) thereafter, 3. mu.L of 100mM chrysosplenetin was applied to the label "1X 10-4Adding 2997 μ L of RPMI Medium 1640 Basic (1X) into the centrifugal tube of mol/L chrysosplenetin + SBFI-26 ″, and mixing by vortex to obtain 1 × 10- 4mol/L chrysosplenetin B;
(2.3) thereafter, 1X 10 of (2.2) were successively sampled-4250, 500 and 750 mu L of chrysosplenetin at mol/L of the mark' 0.25 multiplied by 10-4mol/L chrysosplenetin + SBFI-26, 0.5X 10-4mol/L chrysosplenetin + SBFI-26, 0.75 × 10-4In the centrifugal tubes of mol/L chrysosplenetin + SBFI-26', 10mg/mL SBFI-264.23 mu L is added into each centrifugal tube, and finallySequentially adding 745.77 μ L, 495.77 μ L and 245.77 μ L of RPMI Medium 1640 Basic (1X), and respectively mixing by vortexing; the remaining 1X 10-4Removing 504.23 μ L of the mol/L chrysosplenetin B by suction, adding 10mg/mL SBFI-264.23 μ L, then performing vortex mixing for later use, simultaneously taking 1 μ L DMSO in a centrifugal tube marked with '0.1% DMSO', adding 999 μ L RPMI Medium 1640 Basic (1X), and performing vortex mixing for later use;
(2.4) the cell culture medium in the 96-well plate was discarded, 100. mu.L of the corresponding medium was added to each well, and thereafter, different concentrations (0.25X 10) were used-4mol/L、0.5×10-4mol/L、0.75×10-4mol/L and 1X 10-4mol/L) of chrysosplenetin B and 1 × 10-4Treating cells with mol/L SBFI-26 mixed solution and 0.1% DMSO, culturing in a cell culture box for 24h, and repeating each group for 6 times;
(2.5) then respectively absorbing and removing the culture medium, then adding 100 mu L of new culture medium into each hole, adding 10 mu L of CCK8 reagent, then incubating for 2h at 37 ℃, and then measuring A450 by using a full-automatic enzyme standard instrument;
(5) the viability of the cells was calculated according to the formula (r) and the data was processed analytically using GraphPad Prism software.
As shown in FIG. 3, it can be seen that the test results were 0.25X 10 in comparison with the blank control-4Combination of mol/L chrysosplenetin B and 1X 10-4mol/L SBFI-26 significantly reduced survival of triple negative breast cancer MDA-MB-231 cells by more than 60% (p.ltoreq.0.001), compared with the highest dose (1X 10)-4mol/L) Thelephora minor, the survival rate decreased by 20% above (P.ltoreq.0.001), indicating that Thelephora minor is combined with 1X 10-4The mol/L SBFI-26 can obviously inhibit the MDA-MB-231 cell proliferation of triple negative breast cancer, and the cell proliferation is 0.5 multiplied by 10-4mol/L、0.75×10-4mol/L and 1X 10-4Combination of mol/L chrysosplenetin B and 1X 10-4The proliferation of the triple negative breast cancer MDA-MB-231 cells is also inhibited by mol/L SBFI-26; combining the results of FIGS. 2 and 3, 0.25X 10 was selected-4And (3) carrying out an inhibition experiment of the migration of the triple negative breast cancer cells by using mol/L of chrysosplenin B.
4. Inhibition experiment of chrysosplenetin and SBFI-26 on migration of triple-negative breast cancer cells
(1) Will be at 75cm2Removing old culture medium from triple negative breast cancer MDA-MB-231 cells in logarithmic growth phase in a cell culture bottle, adding 5mL of DPBS buffer solution into the cell culture bottle, then gently shaking, pouring off, adding 5mL of DPBS buffer solution into the cell culture bottle, repeating the cleaning operation once, washing off the old culture medium, adding 3mL of 0.25% Trypsin-EDTA (1X) to digest the cells into single cell suspension, adding the culture medium with the same volume, transferring the single cell suspension into a 15mL centrifugal tube, and centrifuging the single cell suspension for 3min under the condition that the relative centrifugal force is 900 g;
(2) the supernatant after centrifugation was removed, 1mL of RPMI 1640 Basic (1X) was added to the pellet, followed by pipetting to mix well with a pipette, dispersing the cells into a single cell suspension, and then counting the cells.
(3) Thereafter, the cell suspension was diluted to 1-5X 105The cells are inoculated to a 6-well plate (a plurality of parallel lines are drawn on the back of the plate in advance), 2mL of the cells are inoculated to each well, and then the cells are placed in a cell culture box overnight to wait for the cells to grow fully adherent;
(4) preparing DMSO with volume fraction of 0.1% and concentration of 0.25 × 10-4mol/L chrysosplenetin B, 1 × 10-4mol/L SBFI-26 and 0.25X 10-4mol/L of chrysosplenetin B and 1 × 10-4mixing the SBFI-26 with mol/L;
the specific operation is as follows:
(4.1) 4 tubes of 15mL were taken and labeled "0.1% DMSO and 0.25X 10-4mol/L chrysosplenetin B, 1 × 10-4mol/L SBFI-26 and 0.25X 10-4mol/L chrysosplenetin + 1X 10-4mol/L SBFI-26 "; taking 3. mu.L of 100mM chrysosplenetin B to mark 0.25X 10-4Adding 11997 μ L of RPMI Medium 1640 Basic (1X) into the centrifugal tube of mol/L chrysosplenetin, and mixing by vortex to obtain mixture of 0.25 × 10-4mol/L chrysosplenetin B;
(4.2) taking out thereafter 0.25X 10-4mol/L chrysosplenetin 6mL in the mark "0.25X 10-4mol/L chrysosplenetin + 1X 10-4In a mol/LSBFI-26' centrifugal tube, 25.4 microliter is sucked and removed, 25.4 microliter of SBFI-26 with the concentration of 10mg/mL is added, and then the mixture is evenly mixed by vortex for standby; at the same time, 25.4. mu.L of 10mg/mL SBFI-26 is marked with the label "1X 10-4mol/L Adding 5974.6 μ L RPMI Medium 1640 Basic (1X) into a centrifugal tube of SBFI-26' and mixing by vortex for later use; meanwhile, 6 mu L of DMSO is taken out and put in a centrifugal tube marked with 0.1% DMSO, 5994 mu L of RPMI Medium 1640 Basic (1X) is added to be mixed evenly in a vortex mode for later use;
(5) sucking out the culture medium in the culture holes of the 6-hole plate, and scratching the cells by using a 200-microliter gun head perpendicular to the drawn parallel lines, wherein each hole is provided with at least three scratches (a plurality of cross points can be formed and are used as fixed detection points so as to solve the problem of unfixed positions during front and back observation);
(6) carefully washing the scratched cells with DPBS, and observing the scratched cells under an inverted microscope to ensure uniform scratches;
(7) the cell culture medium in the 6-well plate was aspirated off, and then 0.1% DMSO in a volume fraction prepared in advance and a concentration of 0.25X 10 were added to the culture well-4mol/L chrysosplenetin B, 1 × 10-4mol/L SBFI-26 and 0.25X 10-4mol/L of chrysosplenetin B and 1 × 10-42mL of mol/L SBFI-26 mixed solution per well. Control group was supplemented with 0.1% DMSO, and experimental group was supplemented with 0.25X 10 DMSO-4mol/L chrysosplenetin B, 1 × 10-4mol/L SBFI-26 and 0.25X 10-4Combination of mol/L chrysosplenetin B and 1X 10-4Treatment with mol/L SBFI-26, 3 replicates per group, at "5% CO2Culturing for 24 hours in a cell culture box under the condition of 37 ℃;
(7) taking a picture under an inverted microscope, recording and culturing the pore plate, wherein the magnification is 200 times;
(8) processing the image by adopting ImageJ software, and calculating the scratch area;
(9) and analyzing and sorting the area data by adopting GraphPad Prism software.
The results of the experiment are shown in FIGS. 4 and 5, and it can be seen from FIG. 4 that 0.25X 10 is obtained as compared with the blank control-4The mol/L chrysosplenetin can inhibit the migration of triple-negative breast cancer MDA-MB-231 cells; and 0.25X 10 alone-4mol/L chrysosplenetin B, 1 × 10-4mol/L SBFI-26 of 0.25X 10-4Combination of mol/L chrysosplenetin B and 1X 10-4mol/L SBFI-26 almost stopped migration of triple negative breast cancer MDA-MB-231 cells, approaching 90% (figure 5,. x.p. ltoreq.0.001);FIGS. 4 and 5 also show 0.25X 10-4The ratio of mol/L chrysosplenetin B is 1 multiplied by 10-4The mol/L SBFI-26 has good inhibition effect on the MDA-MB-231 cell migration of the triple negative breast cancer; the chrysosplenetin B can inhibit the migration of triple negative breast cancer MDA-MB-231 cells, and the combined drug effect is most obvious.
In conclusion, chrysosplenetin can inhibit the proliferation and migration of triple-negative breast cancer MDA-MB-231 cells, and the combination of SBFI-26 can significantly inhibit the survival, proliferation and migration of triple-negative breast cancer MDA-MB-231 cells.
TABLE 1 reagents and Instrument tables used
The foregoing is illustrative of the preferred embodiments of this invention, and it is to be understood that the invention is not limited to the precise form disclosed herein and that various other combinations, modifications, and environments may be resorted to, falling within the scope of the concept as disclosed herein, either as described above or as apparent to those skilled in the relevant art. And that modifications and variations may be effected by those skilled in the art without departing from the spirit and scope of the invention as defined by the appended claims.
Claims (3)
1. A pharmaceutical composition for inhibiting proliferation and migration of triple negative breast cancer cells, comprising: the pharmaceutical composition comprises chrysosplenetin B and a small molecule inhibitor SBFI-26; the concentration of the chrysosplenetin B is 0.25 x 10 < -4 > -1 x 10 < -4 > mol/L, and the concentration of the small molecular inhibitor SBFI-26 is 1x 10 < -4 > mol/L.
2. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is for inhibiting the proliferation and migration of triple negative breast cancer cells, and wherein: the concentration of the chrysosplenetin B is 0.25 multiplied by 10 < -4 > mol/L, and the concentration of the small molecular inhibitor SBFI-26 is 1 multiplied by 10 < -4 > mol/L.
3. The application of a pharmaceutical composition for inhibiting the proliferation and migration of triple negative breast cancer cells is characterized in that: the use of chrysosplenetin and the small molecule inhibitor SBFI-26 as claimed in claim 1 for preparing a pharmaceutical composition for inhibiting the proliferation and migration of triple-negative breast cancer cells.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111047163.1A CN113855664A (en) | 2021-09-06 | 2021-09-06 | Pharmaceutical composition for inhibiting proliferation and migration of triple negative breast cancer cells and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111047163.1A CN113855664A (en) | 2021-09-06 | 2021-09-06 | Pharmaceutical composition for inhibiting proliferation and migration of triple negative breast cancer cells and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113855664A true CN113855664A (en) | 2021-12-31 |
Family
ID=78994823
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111047163.1A Pending CN113855664A (en) | 2021-09-06 | 2021-09-06 | Pharmaceutical composition for inhibiting proliferation and migration of triple negative breast cancer cells and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113855664A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021108350A1 (en) * | 2019-11-25 | 2021-06-03 | The Research Foundation For The State University Of New York | Combination therapy using fabp5 inhibitors with taxanes for treatment of cancer |
-
2021
- 2021-09-06 CN CN202111047163.1A patent/CN113855664A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021108350A1 (en) * | 2019-11-25 | 2021-06-03 | The Research Foundation For The State University Of New York | Combination therapy using fabp5 inhibitors with taxanes for treatment of cancer |
Non-Patent Citations (2)
| Title |
|---|
| SADHNA SINHA 等: ""Assessment of microtubule depolymerization property of flavonoids isolated from Tanacetum gracile in breast cancer cells by biochemical and molecular docking approach"" * |
| 陈思竹: ""FABP5抑制剂SBFI-26抗乳腺癌作用及机制研究"" * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109371018B (en) | Reinforcing agent for extracting free circulating tumor DNA, kit and method for extracting free circulating tumor DNA in peripheral blood | |
| CN114181903A (en) | Colorectal cancer organoid culture medium and stent-free 3D culture method | |
| CN111218424B (en) | Oxitinib drug-resistant cell strain NCI-H1975/AR and application thereof | |
| CN106480017A (en) | Extract the test kit of circulating tumor cell DNA and tumor dissociative DNA simultaneously | |
| CN113855664A (en) | Pharmaceutical composition for inhibiting proliferation and migration of triple negative breast cancer cells and application thereof | |
| CN104910196B (en) | A kind of chiral copper-based organic metal framework of four core and its preparation method and application | |
| CN106148501A (en) | A kind of kit detecting Septin9 gene methylation and application thereof | |
| CN110464722B (en) | Application of small molecule compound or pharmaceutically acceptable salt thereof in preparation of anti-tumor metastasis drugs | |
| CN106913564B (en) | Use of polyether compound | |
| CN111235218A (en) | Third-generation EGFR-TKI drug-resistant cell strain and application thereof | |
| CN113292546B (en) | Mangiferin derivative and preparation method and application thereof | |
| CN107012207B (en) | Application of LRP5 in clinical diagnosis and inhibition of digestive system tumors | |
| CN114164278A (en) | Marker and kit for auxiliary diagnosis of gastric cancer | |
| CN111690751A (en) | PCR reagent for detecting tumor drug target and application thereof | |
| CN112741080A (en) | Liquid-based cell preservation treatment liquid and preparation method and application thereof | |
| de Almeida et al. | Fine‐needle aspiration cytology as a tool for the early detection of testicular relapse of acute lymphoblastic leukemia in children | |
| Rozencweig et al. | In vitro growth of human malignancies in a cloning assay | |
| CN114164270B (en) | Application of CRIP2 in detecting resistance of prostate cancer to docetaxel and reversing resistance of prostate cancer to docetaxel | |
| Li et al. | Combination Analyses Next Generation Sequencing of Lung Adenocarcinoma ctDNA and CTCs Based on Multi-Site Immunomagnetic Beads | |
| CN115120585B (en) | Artemisinin B for resisting DDP drug-resistant lung adenocarcinoma and pharmaceutical composition thereof | |
| WO2022151520A1 (en) | Primary gastrointestinal stromal tumor cell culture medium, culture method, and application thereof | |
| CN114672564A (en) | Application of TMOD3 and/or ADSL in non-small cell cancer | |
| CN112546050A (en) | Medical application of oleanolic acid | |
| CN111729073A (en) | Application of polypeptide SE37 mutant in preparation of antitumor drugs | |
| CN114250248A (en) | Over-expression RNU12 vector with treatment effect on gastric cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |